The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Efficacy Results of a Trial of a Herpes Simplex Vaccine
Open accessAbstract
BACKGROUND: Two previous studies of a herpes simplex virus type 2 (HSV-2) subunit vaccine containing glycoprotein D in HSV-discordant couples revealed 73% and 74% efficacy against genital disease in women who were negative for both HSV type 1 (HSV-1) and HSV-2 antibodies. Efficacy was not observed in men or HSV-1 seropositive women. METHODS: We conducted a randomized, double-blind efficacy field trial involving 8323 women 18 to 30 years of age who were negative for antibodies to HSV-1 and HSV-2. At months 0, 1, and 6, some subjects received the investigational vaccine, consisting of 20 μg of glycoprotein D from HSV-2 with alum and 3-O-deacylated monophosphoryl lipid A as an adjuvant; control subjects received the hepatitis A vaccine, at a dose of 720 enzyme-linked immunosorbent assay (ELISA) units. The primary end point was occurrence of genital herpes disease due to either HSV-1 or HSV-2 from month 2 (1 month after dose 2) through month 20. RESULTS: The HSV vaccine was associated with an increased risk of local reactions as compared with the control vaccine, and it elicited ELISA and neutralizing antibodies to HSV-2. Overall, the vaccine was not efficacious; vaccine efficacy was 20% (95% confidence interval [CI], -29 to 50) against genital herpes disease. However, efficacy against HSV-1 genital disease was 58% (95% CI, 12 to 80). Vaccine efficacy against HSV-1 infection (with or without disease) was 35% (95% CI, 13 to 52), but efficacy against HSV-2 infection was not observed (-8%; 95% CI, -59 to 26). CONCLUSIONS: In a study population that was representative of the general population of HSV-1- and HSV-2-seronegative women, the investigational vaccine was effective in preventing HSV-1 genital disease and infection but not in preventing HSV-2 disease or infection. (Funded by the National Institute of Allergy and Infectious Diseases and GlaxoSmithKline; ClinicalTrials.gov number, NCT00057330.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trends in Herpes Simplex Virus Type 1 and Type 2 Seroprevalence in the United States
Xu, F., Sternberg, M. R., Kottiri, B. J., McQuillan, G. M., Lee, F. K., Nahmias, A. J., Berman, S. M., & Markowitz, L. E. (2006) · JAMA · doi:10.1001/jama.296.8.964 · Cited by 1,035
Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes
Stanberry, L. R., Spruance, S. L., Cunningham, A. L., Bernstein, D. I., Mindel, A., Sacks, S., Tyring, S., Aoki, F. Y., Slaoui, M., Denis, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011915 · Cited by 794
Self-citationReactivation of Genital Herpes Simplex Virus Type 2 Infection in Asymptomatic Seropositive Persons
Wald, A., Zeh, J., Selke, S., Warren, T., Ryncarz, A. J., Ashley, R., Krieger, J. N., & Corey, L. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421203 · Cited by 582
Self-citationMaternal and Neonatal Herpes Simplex Virus Infections
Corey, L., & Wald, A. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0807633 · Cited by 421
Self-citationRoberts, C. M., Pfister, J. R., & Spear, S. J. (2003) · Sexually Transmitted Diseases · doi:10.1097/01.olq.0000092387.58746.c7 · Cited by 379
Underdiagnosis of Genital Herpes by Current Clinical and Viral-Isolation Procedures
Koutsky, L. A., Stevens, C. E., Holmes, K. K., Ashley, R. L., Kiviat, N. B., Critchlow, C. W., & Corey, L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199206043262305 · Cited by 286
Vyse, A. J. (2000) · Sexually Transmitted Infections · doi:10.1136/sti.76.3.183 · Cited by 189
A Recombinant Glycoprotein Vaccine for Herpes Simplex Type 2: Safety and Efficacy
Langenberg, A. G. M., Burke, R. L., Adair, S. F., Sekulovich, R., Tigges, M., Dekker, C. L., & Corey, L. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-12-199506150-00001 · Cited by 177
Ashley, R. L., Cent, A., Maggs, V., Nahmias, A. J., & Corey, L. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-7-520 · Cited by 149
Ryder, N., Jin, F., McNulty, A. M., et al. (2009) · Sexually Transmitted Infections · doi:10.1136/sti.2008.033902 · Cited by 118
Cited by
Looker, K. J., Magaret, A. S., May, M. T., Turner, K. M. E., Vickerman, P., Gottlieb, S. L., & Newman, L. M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0140765 · Cited by 644
Global Estimates of Prevalent and Incident Herpes Simplex Virus Type 2 Infections in 2012
Looker, K. J., Magaret, A. S., Turner, K. M. E., Vickerman, P., Gottlieb, S. L., & Newman, L. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0114989 · Cited by 519
Seroprevalence of Herpes Simplex Virus Types 1 and 2--United States, 1999-2010
Bradley, H., Markowitz, L. E., Gibson, T., & McQuillan, G. M. (2014) · Journal of Infectious Diseases · doi:10.1093/infdis/jit458 · Cited by 432
Bernstein, D. I., Bellamy, A. R., Hook, E. W., Levin, M. J., Wald, A., Ewell, M. G., Wolff, P. A., Deal, C. D., Heineman, T. C., Dubin, G., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cis891 · Cited by 348
Self-citationThe growing epidemic of sexually transmitted infections in adolescents: a neglected population
Shannon, C. L., & Klausner, J. D. (2018) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000578 · Cited by 298
Understanding and learning from the success of prophylactic human papillomavirus vaccines
Schiller, J. T., & Lowy, D. R. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2872 · Cited by 293
Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies
Bar-Or, A., Pender, M. P., Khanna, R., Steinman, L., Hartung, H.-P., Maniar, T., Croze, E., Aftab, B. T., Giovannoni, G., & Joshi, M. A. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.11.003 · Cited by 262
Inhibition of HSV-1 Replication by Gene Editing Strategy
Roehm, P. C., Shekarabi, M., Wollebo, H. S., Bellizzi, A., He, L., Salkind, J., & Khalili, K. (2016) · Scientific Reports · doi:10.1038/srep23146 · Cited by 128
Masese, L., Baeten, J. M., Richardson, B. A., Bukusi, E., John-Stewart, G., Graham, S. M., Shafi, J., Kiarie, J., Overbaugh, J., & McClelland, R. S. (2015) · AIDS · doi:10.1097/qad.0000000000000646 · Cited by 70
Antiherpes simplex virus type 2 activity of the antimicrobial peptide subtilosin
Quintana, V. M., Torres, N. I., Wachsman, M. B., Sinko, P. J., Castilla, V., & Chikindas, M. (2014) · Journal of Applied Microbiology · doi:10.1111/jam.12618 · Cited by 69
Celum, C., Morrow, R. A., Donnell, D., Hong, T., Hendrix, C. W., Thomas, K. K., Fife, K. H., Nakku-Joloba, E., Mujugira, A., Baeten, J. M., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2471 · Cited by 61
Self-citation
Metadata
- Authors
- Belshe, R. B., Leone, P. A., Bernstein, D. I., Wald, A., Levin, M. J., Stapleton, J. T., Gorfinkel, I., Morrow, R. L. A., Ewell, M. G., Stokes-Riner, A., Dubin, G., Heineman, T. C., Schulte, J. M., & Deal, C. D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-01-05
- Volume
- 366
- Issue
- 1
- Pages
- 34-43
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140811217
- Cited by
- 510
- References
- 15
- FWCI
- 38.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.